Donald G. Hildebrand - Chairman
Andrew J. Kandalepas
Dean G. Kollintzas
Robert T. McNally
Harriet L. Robinson
John "Jack" N. Spencer - Chairman of the Audit and Compensation Committees
Donald Hildebrand is a co-founder of GeoVax Labs and has more than 30 years of successful experience managing biotechnology and biopharmaceutical companies. During his career, he has led teams developing, licensing and commercializing some of the world’s leading vaccines and pharmaceutical products.
As North American President and CEO of Rhone Merieux, Inc., Mr. Hildebrand grew the company from a staff of five and no sales to more than 1,100 employees and annual sales exceeding $200 million. When Rhone Merieux merged with Merial, Ltd., Mr. Hildebrand was promoted to Global Vice President, responsible for research, product development, technical services and business development of worldwide biological activities. He was a member of Merial’s Executive Committee. Merial is the world’s largest animal health company, with annual sales exceeding $2 billion and a $120 million research budget.
Previously, Hildebrand founded Biocraft, Ltd., which was later sold to Solvay & Cie of Brussels, Belgium. Subsequently, he became Solvay’s Director of Global Biological Operations, Research, Development and Manufacturing. This company is currently owned by American Home Products.
Mr. Hildebrand has served on the Board of Directors of Select Laboratories, Inc., University of Georgia Research Foundation, Vaxin Pharmaceuticals, Inc., First American Bancorp of Georgia/First American Bank, Rhone Merieux, Inc., RM de Mexico, Inc., RM Technologies, Inc., Biocraft Ltd., University of Wisconsin – SCVM Board of Visitors, and the Athens, Ga. Economic Development Foundation.
Hildebrand has a Microbiology degree from the University of Wisconsin-Madison and has taken advanced management courses at Harvard Business School and Marquette University.
back to top
Mr. Kandalepas was formerly the Chief Executive Office and Chairman of the Board of Dauphin Technology, Inc., Under his leadership, which began in 1995, Dauphin Technology developed and marketed several well known high tech products, including, miniature hand held computers and Set Top Boxes. During his tenure at Dauphin, Mr. Kandalepas was successful in raising in excess of $60M in private and public capital as well as expanding Dauphin’s shareholder base from 400 shareholders in 1995 to approximately 25,000 shareholders.
Mr. Kandalepas has extensive career as an entrepreneur and executive manager which spans more than 30 years. Following 12 successful years with GTE and Motorola, he founded Cadserv Corporation, a privately owned Engineering and Circuit Board Solutions boutique service provider to major electronic OEM’s.
Mr. Kandalepas is an active participant in the local Greek community and served as a founder of the St. Athanasios Greek Orthodox Seminary in Woodstock, Illinois. He earned his Electronics Engineering Degree in 1974 from the DeVry Institute of Technology.
back to top
Mr. Kollintzas is an Intellectual Property Attorney specializing in biotechnology and pharmaceutical licensing, FDA regulation, and corporate/international transactions. He has worked in Israel as a U.S. consultant to the firm of Baratz, Gilat, Bar-Natan with biotechnolgy companies such a Clal Biotechnology Industries Limited and D-Pharm.
As an associate with the firm LaFollette, Godfrey & Kahn in Madison, Wisconsin, Mr. Kollintzas worked with the Wisconsin Alumni Research Foundation "WARF" on various FDA and intellectual property engagements as well as many of its commercialization efforts.
Mr. Kollintzas received a Microbiology degree from the University of Illinois and a J.D. from Franklin Pierce Law Center. He is a member of the Wisconsin and American Bar Associations.
back to top
Dr. Robert McNally graduated with a Ph.D. in Biomedical Engineering from the University of Pennsylvania and has over 28 years of experience in academic and corporate clinical investigations, management, research, business, quality and regulatory affairs.
Dr. McNally is the President and CEO of GeoVax. Previously, he served as President as well as VP of Quality Assurance of Cell Dynamics, a company he co-founded. Cell Dynamics worked with organ and tissue procurement organizations for the recovery of human tissue processing these tissues into cellular components necessary for research and development, pharmaceuticals and cell therapy. In 1984, Dr. McNally co-founded CryoLife, Inc., a company specializing in the cryopreservation of human tissue for transplant. During his 14 year association with CryoLife, it grew to $50M in revenue, became a public company on NYSE and received world recognition as a leader in transplant technology.
He is a Fellow of the American Institute of Medical and Biological Engineers, serves on the board of the Petit Institute for Tissue Engineering at Georgia Tech and is Past Chairman of the Georgia Biomedical Partnership and recipient of its 2005 Biomedical Industry Growth Award.
back to top
Dr. Robinson is the developer of GeoVax' HIV-1 AIDS vaccine technology. One of the world's leaders in AIDS vaccine research, she currently serves as Senior Vice President of Research and Development for GeoVax. Previously, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University.
Dr. Robinson has published extensively on HIV-AIDS vaccine research as well as viral-induced cancers. Her pioneering studies on the development of DNA vaccines demonstrated not only that DNA could raise protective immunity for viral infections, but also identified methods of DNA delivery that could be used to control the type of immune responses raised by DNA vaccines.
Her early work with HIV vaccines demonstrated that DNA alone would not be sufficient to raise protective immunity for HIV. She then combined DNA with protein boosters or live viral-vectored boosters to show that the most effective control was through a combination of DNA prime and viral-vectored boosters. Her most recent work has developed single mutiprotein expressing DNA, and working with the NIAID-NIH, a single poxvirus vector (MVA) has been developed to be used for priming and boosting. It is these vaccines that GeoVax has licensed for commercial development.
Dr. Robinson has published extensively on HIV-AIDS vaccine research with more than 130 referred scientific journal publications, 45 monograph reviews and 6 book chapters authored. She has consulted for the US National Insitutes of Health, the US Food and Drug Administration, the Bill and Melinda Gates Foundation, and the World Health Organization.
Dr. Robinson received her B.A. from Swarthmore College and took her PhD in Microbiology from Massachusetts Institute of Technology. She has been elected to the American Academy of Microbiology.
back to top
Mr. Spencer served a broad range of clients for several years at Ernst & Young. He worked in the firm’s national office in New York assisting the development of professional policies and resolving client matters nationwide in the audit, accounting and SEC areas. Jack served as the Managing Partner of their Rhode Island office before transferring to Atlanta. He was the Market Segment Team Leader for Ernst & Young’s Life Sciences industry practice in the Southeast. He retired in 2000.
Mr. Spencer served as coordinating partner for clients principally in the manufacturing, distribution and/or technology industries, including two Fortune 500 manufacturing companies. He has significant expertise in coordinating services to publicly held companies, including involvement in more than 200 registration statements and over 25 initial public offerings. He provided audit and financial related services for over 100 merger and acquisition transactions. He has worked with many Boards and Audit Committees.
Active in Georgia’s technology community, he served as president and a director of the Business and Technology Alliance (“B&TA”). He was a cofounder and is treasurer of the Atlanta Venture Forum, an association of venture capital investors in the Southeast, and he recently completed two years as the President of the Georgia Biomedical Partnership. In addition, he was a cofounder of the Technology Hall of Fame of Georgia. In January 2002, Jack was awarded the Georgia Biomedical Partnership’s First Annual award for being a principal architect of the biomedical community in Georgia. In September 2002, the Atlanta Business Chronicle included him in its list of “25 Names To Know In Atlanta Biotechnology.”
Jack is a member of the National Association of Corporate Directors, and he serves as a member of the Board of Directors of: A C Therapeutics, Inc.; GeneEx, Inc.; and OrthoHelix Surgical Designs, Inc. He also serves on the Board of Directors of Firstwave Technologies, Inc. (Nasdaq – FSTW) and is the Chair of its Audit Committee. In addition, Jack is a Director of BioFlorida and the Georgia Biomedical Partnership.
Jack holds a Bachelor of Science degree from Syracuse University where he serves on the Accounting Faculty Advisory Board, and he earned a Master of Business Administration degree from Babson College. He also completed the Harvard Business School’s Advanced Management Program.
back to top